Printer Friendly

THE LIPOSOME COMPANY, INC. STARTS PHASE III ABLC TRIALS IN SOUTH AFRICA -- DRUG BEING TESTED IN AIDS RELATED FUNGAL INFECTIONS --

 PRINCETON, N.J., Nov. 23 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO and LIPOZ) has initiated a Phase III clinical study of its drug ABLC(TM) (amphotericin B lipid complex) in AIDS patients with cryptococcal meningitis in the Republic of South Africa.
 Cryptococcal meningitis is a type of fungal infection, which attacks patients' central nervous systems and occurs in up to 10 percent of patients with AIDS. About 20 percent of patients die within 30 days of diagnosis.
 The first patient in the study was treated at Ernest Oppenheimer Hospital. A total of 10 centers in South Africa are expected to participate in the study, which is targeted for completion in 1994. In addition, a second Phase III clinical study in systemic cryptococcosis, a related disease which primarily affects the lungs, is being started. The Liposome Company also recently started named patient distribution of ABLC in South Africa.
 "We have previously seen encouraging results from a randomized comparative Phase II trial of ABLC versus conventional amphotericin B in the treatment of cryptococcal meningitis in AIDS patients," said Charles A. Baker, chairman and chief executive officer. "Due to the AIDS epidemic in Africa, we believe we can efficiently conduct a larger Phase III study in cryptococcal meningitis in South Africa to confirm the efficacy and safety of ABLC. The study will be conducted by investigators at 10 hospitals, which have large AIDS populations. We anticipate that the data generated will be useful for expanding ABLC's data package in many countries worldwide."
 In addition, The Liposome Company is preparing applications for approval to market ABLC in Europe. ABLC is already available on a compassionate use basis in the U.S. and Europe for patients with life-threatening systemic fungal infections for whom currently marketed drugs are ineffective or too toxic. To date, about 300 patients in the U.S. compassionate use program have received ABLC. Several hundred more have been treated in controlled clinical trials in the U.S. Large U.S. Phase III trials in several types of life-threatening systemic fungal infections are now being planned.
 ABLC, a proprietary new drug, consists of amphotericin B in a lipid complex. Conventional amphotericin B, without the lipid complex, is a broad-spectrum polyene antifungal agent which has been marketed for many years for the treatment of systemic fungal infections in patients who are immunocompromised, such as people with AIDS, cancer chemotherapy patients and organ transplant recipients. While the old version of amphotericin B generally is considered the "gold standard" treatment against such infections as candidiasis, cryptococcal meningitis and aspergillosis, its usefulness has been limited by its potential to cause side effects, especially kidney toxicity and anemia. By incorporating amphotericin B in a lipid complex, clinical results to date indicate that ABLC may significantly reduce the risk of toxicity while maintaining or increasing efficacy.
 The Liposome Company has four drugs currently in clinical trials. ABLC is in Phase II/III studies for the treatment of systemic fungal infections in the U.S.; MAITEC(TM) (formerly TLC G-65) is in Phase II trials in the U.S. and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 has completed Phase II trials for treatment of metastatic breast cancer; and TLC C-53 has completed Phase I trials in preparation for studies in Acute Respiratory Distress Syndrome.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening disease.
 -0- 11/23/93
 /CONTACT: Brooks Boveroux, vice president, finance and chief financial officer of The Liposome Company, Inc., 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU:

LD -- NY009 -- 7103 11/23/93 08:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 23, 1993
Words:636
Previous Article:QUADRAX CORPORATION ANNOUNCES PROCEEDS OF APPROXIMATELY $2 MILLION THROUGH REDEMPTION OF WARRANTS
Next Article:BARNES & NOBLE, INC. REPORTS REVENUE GAIN OF 22 PERCENT IN THIRD QUARTER RESULTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters